Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.35 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.35 |
| ▸ | TAOK3 | Q9H2K8 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4237167 | 0.78 | MTNR1A (0.39) | HTTALDH1A1KMT2AKDM4E | |
| Trifluoroacetic Acid SCHEMBL4226991 | 0.69 | KDM1A (0.56) | — | |
| Trifluoroacetic Acid SCHEMBL4226583 | 0.68 | MTNR1A (0.53) | — | |
| SCHEMBL9568030 | 0.64 | ALDH1A1 (0.45) | HTTALDH1A1XBP1 | |
| Hydrochloric Acid SCHEMBL4235489 | 0.64 | GRIN2B (0.52) | MEN1KMT2AKDM4E | |
| SCHEMBL5901234 | 0.63 | HTT (0.61) | HTTALDH1A1MEN1KMT2AGAA | |
| Trifluoroacetic Acid SCHEMBL3722524 | 0.63 | HTT (0.47) | HTTALDH1A1MEN1KMT2AOPRD1 | |
| Trifluoroacetic Acid SCHEMBL18440248 | 0.63 | HTT (0.36) | HTT | |
| SCHEMBL3600888 | 0.62 | IDO1 (0.41) | TAS1R3TAS1R1TAS1R2 | |
| Trifluoroacetic Acid SCHEMBL4380019 | 0.62 | SSTR4 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2096104-A1 | Organic diamines as mGluR7 modulators | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080242698-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242698-A1 | Organic Compounds | AOC1, OTC, ODC1 | HTT 3311/4885ALDH1A1 266/4885MEN1 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.